Skip to content
Screener

Opus Genetics IRD Income Statement

Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
Total revenue
$755K-73.8%$2.16M-50.6%$3.87M-10.2%$3.08M-20.4%$2.88M+159%
Research and development
$11.21M—$10.58M+33.0%——$6.41M-28.6%——
General and administrative
$6.03M+4.5%$5.94M-6.3%$4.89M-33.0%$4.98M+72.1%$5.77M+71.9%
Total operating expenses
$17.24M+46.2%$16.52M+15.5%$15.32M-63.8%$11.39M-4.1%$11.79M+24.9%
Operating income
-$16.48M-85.0%-$14.36M-44.7%-$11.45M+69.9%-$8.31M-3.8%-$8.91M-6.9%
Operating margin
-2,182.8%-1,874pp-665.9%-439pp-296.3%+588pp-269.9%-62.8pp-309%+440pp
Interest expense
$74K—$69K—$61K—$68K—$0—
Other income (expense), net
$1.74M+226%$844K+179%$703K-75.1%$450K-6.8%$534K-5.2%
Income before income taxes
-$8.1M-9.1%-$65.54M-700%-$16.52M+53.0%-$17.45M-132%-$7.42M+4.4%
Income tax expense
$0—$0—$0—$0—$0—
Net income
-$8.1M-9.1%-$65.54M-700%-$16.52M+53.0%-$17.45M-132%-$7.42M+4.4%
Net margin
-1,072.6%-815pp-3,038.2%-2,851pp-427.5%+389pp-566.9%-372pp-257.5%+441pp
Diluted earnings per share
-$0.14-16.7%-$0.75-213%-$0.21+83.5%-$0.25+13.8%-$0.12+60.0%
EBITDA
-$16.47M-85.2%-$14.35M-44.7%-$11.44M+69.9%-$8.3M-3.6%-$8.89M-6.8%
EBITDA margin
-2,180.9%-1,872pp-665.3%-438pp-296%+588pp-269.5%-62.4pp-308.5%+440pp
EBIT
-$16.48M-85.0%-$14.36M-44.7%-$11.45M+69.9%-$8.31M-3.8%-$8.91M-6.9%

FAQ

What is Opus Genetics's revenue?
Opus Genetics (IRD) generated $9.9M in revenue over the trailing twelve months, down 36.1% year over year.
Is Opus Genetics profitable?
Opus Genetics is not currently profitable: it reported a net loss of $107.6M over the trailing twelve months, a -1091.8% net margin.
What is Opus Genetics's earnings per share?
Opus Genetics's diluted EPS over the trailing twelve months is $-1.35.
Where does Opus Genetics's income statement data come from?
Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.